Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 06, 2023

Amivantamab Plus Lazertinib for Osimertinib-Relapsed EGFR-Mutant Advanced NSCLC

Nature Medicine


Additional Info

Nature Medicine
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Nat. Med. 2023 Sep 14;[EPub Ahead of Print], BC Cho, DW Kim, AI Spira, JE Gomez, EB Haura, SW Kim, RE Sanborn, EK Cho, KH Lee, A Minchom, JS Lee, JY Han, M Nagasaka, JK Sabari, SI Ou, P Lorenzini, JM Bauml, JC Curtin, A Roshak, G Gao, J Xie, M Thayu, RE Knoblauch, K Park

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading